| Ref ID | 747 |
| First Author | C. Benea |
| Journal | SYSTEMATIC REVIEWS |
| Year Of Publishing | 2020 |
| URL | https://www.ncbi.nlm.nih.gov/pubmed/32268911 |
| Keywords |
• Allegiance • General medical • Disclosure • Non-Cochrane reviews • Cochrane |
| Problem(s) |
• Conflict of interest statement or disclosures for review authors missing • Cochrane reviews more rigorous/higher quality than non-Cochrane reviews • Funding or sponsor of systematic review not reported |
| Article Type | Empirical |
| Article Subtype | Cross-sectional survey/Methodological systematic review |
| First Author Country | Canada |
| Aim | To assess the extent to which pharmaceutical industry funding and author-industry financial conflicts of interest and employment from included drug trials are reported in systematic reviews with meta-analyses published in between Jan 2017 and Oct 2018 in high-impact journals and to compare current reporting with results from 2009. |
| Level of Investigation | Descriptive |
| Summary of Findings | Reporting of drug trial sponsorship and author financial conflicts of interest in meta-analyses published in high-impact journals increased since 2009 but was still suboptimal. Among 29 meta-analyses reviewed, 13 of 29 (44.8%) reported the funding source of included trials compared to 2 of 29 (6.9%) in 2009, a difference of 37.9% (95% confidence interval, 15.7 to 56.3%); this included 7 of 11 (63.6%) from general medicine journals, 3 of 15 (20.0%) from specialty medicine journals, and 3 of 3 (100%) Cochrane reviews. Only 2 of 29 meta-analyses (6.9%) reported trial author financial conflicts of interest, and none reported trial author-industry employment. |
| Number of systematic reviews included | 29 |
| Number of eligible systematic reviews assessed | 176 |